RAYMOND L. RICE, M.D., M. SC. (Med.), F.A.C.P.; JACK S. ACKERMAN, M.D.; ROBERT SAICHEK, M.D.
This content is PDF only. Please click on the PDF icon to access.
Ground work in the use of Dicumarol for preventing the extension of coronary thrombosis and the development of mural thrombi in the presence of myocardial infarction was laid by Solandt, Nassim, and Best1 in 1938. Using the anticoagulant, heparin, they were able to prevent the formation of coronary thrombi and intracardiac mural thrombi when deliberate experiments were performed to produce these lesions in experimental animals.
With the advent of Dicumarol numerous workers2, 3, 4 began its use in the treatment of coronary thrombosis with myocardial infarction and its complications.
Recently the Committee for the Evaluation of Anticoagulants in the Treatment
RICE RL, ACKERMAN JS, SAICHEK R. LONG TERM DICUMAROL THERAPY*. Ann Intern Med. 1950;32:735–745. doi: https://doi.org/10.7326/0003-4819-32-4-735
Download citation file:
Published: Ann Intern Med. 1950;32(4):735-745.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use